J&J Can't Get New Trial Over $1.2B Ark. Risperdal Fine

Law360, New York (June 20, 2012, 7:30 PM EDT) -- An Arkansas judge on Tuesday denied a new trial for Johnson & Johnson and a subsidiary after fining them $1.2 billion in April after a jury sided with the state in a suit alleging the companies committed Medicaid fraud by illegally marketing antipsychotic drug Risperdal.

Arkansas brought the suit in November 2007 to recover the money it paid to provide Risperdal to patients through Medicaid and other programs. It argued that J&J and its unit Janssen Pharmaceuticals Inc. misrepresented the drug's risks to patients and promoted...
To view the full article, register now.